65 filings
8-K
IBRX
ImmunityBio Inc
12 Jun 24
Submission of Matters to a Vote of Security Holders
4:36pm
8-K
IBRX
ImmunityBio Inc
23 Apr 24
ImmunityBio Announces FDA Approval of ANKTIVA®, First-in-Class
6:17am
8-K
IBRX
ImmunityBio Inc
23 Feb 24
Departure of Directors or Certain Officers
9:28pm
8-K
IBRX
ImmunityBio Inc
2 Jan 24
ImmunityBio Announces $320 Million Investment by Oberland
6:08am
8-K
IBRX
ImmunityBio Inc
11 Sep 23
ImmunityBio Announces $470 Million Equity and Debt Financing
6:25am
8-K
0xh apmyp2k7krshhw
1 Sep 23
Other Events
8:30am
8-K
56f5b
15 Aug 23
Other Events
4:15pm
8-K
8d26fz h0sjhwvcy
21 Jul 23
ImmunityBio Announces Execution of $40 Million Equity Financing with Institutional Investors
6:04am
8-K
8hkpe29zm78gewt3
20 Jul 23
Other Events
4:07pm
8-K
ozf2v
14 Jun 23
Entry into a Material Definitive Agreement
5:15pm
8-K
empgyf09xq7z9om
11 May 23
Other Events
6:45am
8-K
kk9ybmtq107uj
31 Mar 23
Entry into a Material Definitive Agreement
4:29pm
8-K
8s67hev5zmvp7wv7
20 Mar 23
Other Events
8:31am
8-K
yp0 1cwrw8mehu1jk
15 Feb 23
ImmunityBio Announces Execution of $50 Million Equity Financing with Multiple Institutional Investors
9:20am
8-K
ee4biqefezi m1v8
14 Feb 23
Results of Operations and Financial Condition
5:25pm
8-K
lf0fr
13 Feb 23
Other Events
8:02am
8-K
1pih 3rneomcwnv4dle
12 Dec 22
ImmunityBio Announces $157 Million Financing From Nant and Institutional Investor
9:07am
8-K
z2j adagoas0b
5 Dec 22
Other Events
10:51am
8-K
e8o7w l0d6mh8po
15 Nov 22
Regulation FD Disclosure
8:42am
8-K
anwt hdwq8l
2 Sep 22
Entry into a Material Definitive Agreement
4:15pm